TITLE

Discovery research to clinical trial: A ten year journey

AUTHOR(S)
Nielsen, Torsten O.
PUB. DATE
December 2010
SOURCE
Clinical & Investigative Medicine;Dec2010, Vol. 33 Issue 6, pE342
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Clinician-scientists have the training and motivation to translate basic science into tools for improved clinical care, but the road to achieve this is hardly straight forward, particularly for large scale genomic datasets. !is year’s Joe Doupe Young Investigator award winner, Dr. Torsten Nielsen, details successful examples of new scienti"c insights, diagnostics and clinical trials that have resulted from microarray-based gene expression pro"ling of sarcomas: TLE1 as a biomarker for synovial sarcoma, histone deacetylase inhibitor therapy for translocation-associated sarcomas of young adults, and CSF1 pathway inhibitors for tenosynovial giant cell tumors. Results from exciting, emerging next generation sequencing technologies will need to undergo similar validation and preclinical studies before they can be expected to impact patient care.
ACCESSION #
61180826

 

Related Articles

  • Development and validation of a novel molecular biomarker diagnostic test for the early detection of sepsis.  // Critical Care;2011, Vol. 15 Issue 3, p1 

    The article focuses on the study regarding molecular gene expression biomarkers diagnostic test development and validation for sepsis early detection. The clinical trial utilized the collection of 5 milliliters (ml) of blood for gene expression analyses and leucocyte RNA isolation on...

  • Recent advances in histone deacetylase targeted cancer therapy. Hoshino, Isamu; Matsubara, Hisahiro // Surgery Today;Sep2010, Vol. 40 Issue 9, p809 

    Epigenetic regulators such as histone acetyltransferases (HATs) and histone deacetylases (HDACs) are known to play an important role in gene expression. Of these enzymes, HDACs have been shown to be commonly associated with many types of cancers and to affect cancer development. Consequently,...

  • Predicting Response to Histone Deacetylase Inhibitors Using High-Throughput Genomics. Geeleher, Paul; Loboda, Andrey; Lenkala, Divya; Fan Wang; LaCroix, Bonnie; Karovic, Sanja; Wang, Jacqueline; Nebozhyn, Michael; Chisamore, Michael; Hardwick, James; Maitland, Michael L.; Huang, R. Stephanie; Wang, Fan // JNCI: Journal of the National Cancer Institute;Nov2015, Vol. 107 Issue 11, p1 

    Background: Many disparate biomarkers have been proposed as predictors of response to histone deacetylase inhibitors (HDI); however, all have failed when applied clinically. Rather than this being entirely an issue of reproducibility, response to the HDI vorinostat may be determined...

  • Inhibitory deacetylaz histonów - mechanizmy dziaÅ‚ania na poziomie molekularnym i zastosowania kliniczne. Grabarska, Aneta; Dmoszyńska-Graniczka, Magdalena; Nowosadzka, Ewa; Stepulak, Andrzej // Advances in Hygiene & Experimental Medicine / Postepy Higieny i ;2013, Vol. 67, p722 

    Histone deacetylases (HDACs) play an important role in the epigenetic regulation of gene expression implicated in cancer pathogenesis. Inhibitors of HDACs (HDI) are under investigation as novel anti-cancer drugs, which induce histone hyperacetylation. These agents modulate chromatin structure...

  • Role of microRNAs in diagnosis and treatment of the pathogenesis of gastric cancer. Gang Chen; Yong Tang; Jiang-Hua Wu; Feng-Hua Liu // International Journal of Clinical & Experimental Medicine;2014, Vol. 7 Issue 12, p5947 

    We aim to detect the miRNAs that are correlated with the gastric cancer cell line SGC-7901 to provide theoretical basis for clinical application. We first analyzed miRNA expression profiles of gastric cancer patients compared with normal controls by microarray analysis and validated the results...

  • blood biomarkers - is there future?  // Annals of Oncology;Mar2011 Supplement 2, Vol. 22 Issue suppl_2, pii27 

    No abstract available.

  • Screening Technologies for Target Identification in Pancreatic Cancer. Michl, Patrick; Ripka, Stefanie; Gress, Thomas; Buchholz, Malte // Cancers;2011, Vol. 3 Issue 1, p79 

    Pancreatic cancer exhibits an extraordinarily high level of resistance to almost any kind of systemic therapy evaluated in clinical trials so far. Therefore, the identification of novel therapeutic targets is urgently required. High-throughput screens have emerged as an important tool to...

  • Plakoglobin is a new target gene of histone deacetylase in human fibrosarcoma HT1080 cells. Joong Sup Shim; Dong Hoon Kim; Ho Jeong Kwon // Oncogene;3/4/2004, Vol. 23 Issue 9, p1704 

    Histone deacetylase (HDAC) plays a key role in gene expression, by suppressing the transcription of a number of target genes. Identification of such genes is important for deciphering the functional role of HDAC. Here, using cancer gene-focused DNA microarray analysis, we identified plakoglobin...

  • A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocationassociated recurrent/metastatic sarcomas--NCIC-CTG IND 200. Chu, Q. S.-C.; Nielsen, T. O.; Alcindor, T.; Gupta, A.; Endo, M.; Goytain, A.; Xu, H.; Verma, S.; Tozer, R.; Knowling, M.; Bramwell, V. B.; Powers, J.; Seymour, L. K.; Eisenhauer, E. A. // Annals of Oncology;May2015, Vol. 26 Issue 5, p973 

    Background: A subgroup of sarcomas is characterized by defining chromosomal translocations, creating fusion transcription factor oncogenes. Resultant fusion oncoproteins associate with chromatin-modifying complexes containing histone deacetylases (HDAC), and lead to epigenetic transcriptional...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics